Program 3: Cancers with Instability of Microsatellites (MSI)

Cancers with microsatellite instability (MSI)

Coordinated by Pr. Alex Duval

Cancers with instability of DNA microsatellite repeat sequences (MSI) constitute a family of frequent tumors, associated with numerous localizations (colon, stomach, endometrium, pancreas, prostate, lung, breast, ovary, brain, etc.). The main objectives of this program, dedicated to MSI cancers of all locations, are:

  • Understand the processes that underlie MSI tumor initiation and progression and shape the microenvironment of these cancers.
  • To develop new diagnostic tools and therapeutic regimens adapted to their modern management by precision medicine in full emergence (immunotherapy, inhibitors of immune checkpoints).

 

 


Synthesis for the general public

[ESMO 2019] Efficacy of PD-1 Inhibitors Confirmed in the Treatment of “MSI” Tumours

The pooled analysis of two studies, KEYNOTE-164 and KEYNOTE-168, in which Pr Thierry André, Head of the Digestive Oncology Department […]

Read more

Treatment of gastrointestinal MSI cancers by immuno-oncology

How to Improve the Results With IO Agents in MSI GI Cancer?   https://oncologypro.esmo.org/content/download/231632/3918938/version/1/file/WORLDGI2019_76_andre.pdf

Read more

Pembrolizumab in Colorectal Cancer – Stage IV MSI-H – KEYNOTE-164 (NCT02460198)

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Le DT, Kim TW, Van […]

Read more

ASCO 2020 – Plenary session – Pr Thierry André

ASCO Annual Congress – Plenary session – Pr Thierry André The Congress of the American Society of Clinical Oncology (ASCO) […]

Read more